The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Julie M. Vose (Profiled Author: Julie Marie Vose)
American Journal of Hematology 2012;87(6):604-609.Abstract
Disease Overview: Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood, and bone marrow with a short remission duration to standard therapies and a median overall survival of 4-5 years. Diagnosis: Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation t(11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1. Cyclin D1 is detected by immunohistochemistry in 98% of cases. The absence of SOX-11 or a low Ki-67 may correlate with a more indolent form of MCL. The differential diagnosis of MCL includes small lymphocytic lymphoma, marginal zone lymphoma, and follicular lymphoma. Risk Stratification: The mantle cell lymphoma international prognostic index (MIPI) is the prognostic model most often used and incorporates ECOG performance status, age, leukocyte count, and lactic dehydrogenase. A modification of the MIPI also adds the Ki-67 proliferative index if available. The median overall survival (OS) for the low-risk group was not reached (5-year OS of 60%). The median OS for the intermediate risk group was 51 and 29 months for the high-risk group. Risk-Adapted Therapy: For selected indolent, low MIPI MCL patients, initial observation may be appropriate therapy. For younger patients with intermediate or high risk MIPI MCL, aggressive therapy with a cytarabine containing regimen ± autologous stem cell transplantation should be considered. For older MCL patients with intermediate or high risk MIPI, combination chemotherapy with R-CHOP, R-Bendamustine, or a clinical trial should be considered. At the time of relapse, agents directed at activated pathways in MCL cells such as bortezomib (NFkB inhibitor), BTK inhibitors or CAL-101 (B-cell receptor inhibitors) or lenalidamide (antiangiogenesis) have clinical activity in MCL patients. Autologous or allogeneic stem cell transplantation can also be considered in young patients. © 2012 Wiley Periodicals, Inc.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Keni Gu; Dennis D. Weisenburger; Kai Fu; Wing C. Chan; Timothy C. Greiner; Patricia Aoun; Lynette M. Smith; Martin Bast; Zhongfen Liu; R. Gregory Bociek; et al.Hematological Oncology 2012;30(3):143-149.
Monica Testoni; Ivo Kwee; Timothy C. Greiner; Santiago Montes-Moreno; Julie Vose; Wing C. Chan; Annalisa Chiappella; Luca Baldini; Andrés J.M. Ferreri; Gianluca Gaidano; et al.British Journal of Haematology 2011;155(2):274-277.
Javeed Iqbal; Paul N. Meyer; Lynette M. Smith; Nathalie A. Johnson; Julie M. Vose; Timothy C. Greiner; Joseph M. Connors; Louis M. Staudt; Lisa Rimsza; Elaine Jaffe; et al.Clinical Cancer Research 2011;17(24):7785-7795.
Appears in this Document